New asthma drug aims to cut severe attacks in Half-Year trial
NCT ID NCT07372287
Summary
This study is testing an investigational injection called CM326 to see if it can reduce severe asthma flare-ups and improve lung function and quality of life in adults with moderate to severe asthma. About 230 participants will receive either CM326 or a placebo injection for 52 weeks, followed by a safety check. The main goal is to see if CM326 lowers the yearly rate of severe asthma attacks that require emergency care or steroids.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.